NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Hankmanhub, only about 15% of the GBM population had the Proneural antigenic type and DCVax-L is Per Dr. Liau not very effective for that type of cancer.

Consequently, not much revenue will be lost by removing this small group from the GBM category especially when the DCVax-L treatment does not work well in such patients.

Furthermore, I am betting that in the future a lot of revenue will be earned from the treatment of a variety of solid inoperable cancers with DCVax-
Direct and from DCVax-L designed to treat a variety of operable cancers.